iFast Diagnostics

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Health and bioDeveloper tools and cloud

iFast Diagnostics has no funding amount on record yet; its latest known round is Seed (May 2026). Recent Funding first saw it on October 2, 2026.

Raise history

1. May 27, 2026
   Seed · amount undisclosed
   Source: crunchbase.com

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/ifast-diagnostics.